TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications. 

TCT 2023 | SWEDEHEART, evolución  a 5 años

The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal) compared T-TEER against medical treatment and did not find differences in mortality or CF related hospitalization at 1 year, but did observe improved health status with T-TEER.

The aim of this prospective, multicenter and randomized study was to assess the benefit of T-TEER in health status. 

Health status was measured by the Kansas questionnaire (KCCQ, Kansas City Cardiomyopathy Questionnaire) based on time reference points: at kickoff, 1 month, 6 months and 1 year. 

Read also: TCT 2023 The LIFE-BTK Trial.

A total 350 patients were randomized: 175 to receiving T-TEER and 175 to medical treatment (MT). Mean age was 78, and most patients were women. At 1 month, T-TEER resulted in improved health status and showed continuous improvement at 1 year, vs. MT. Patients undergoing T-TEER saw better survival and good health status at one year, vs MT patients (74,8% vs. 45,9%, p<0,001) with necessary number to treat (NNT) 3.5.

Conclusion

In conclusion, in this study, patients treated with T-TEER experienced improved health status vs patients receiving MT alone, and this improvement was more evident in patients with symptomatic TR. Improved health status was more evident at 1 month and was maintained at 1 year followup. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Health Status after Transcatheter Tricuspid-Valve Repair in Patients with Severe Tricuspid Regurgitation: Results from the TRILUMINATE Pivotal Trial.

Reference: Suzanne V. Arnold, MD MHA et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...